Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops

ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is being conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNFa. It is being developed initially for ophthalmic indications.

In previously reported in vivo, preclinical studies, ESBA105 achieved high therapeutic concentrations in all ocular tissues, when delivered topically via eye drops. Therapeutic concentrations of ESBA105 were observed throughout the anterior (front) and the posterior (back) segments of the eye, the latter including the vitreous humor, retina and choroid.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, commented, "ESBA105 shows an entirely novel and unique intraocular distribution pattern upon topical administration to the eye. Therapeutic levels are reached in both the aqueous and vitreous humor after only a couple of hours following initiation of treatment. Our in vivo, preclinical studies have shown that ESBA105 has a prolonged half-life of 25 hours in the vitreous. Thus, the vitreous acts as a natural depot compartment for ESBA105, allowing for highly attractive maintenance dosing regimens. TNFa is a rapidly emerging target in ophthalmology and ESBA105 has the potential to be a significant advancement in anti-inflammatory ophthalmic medicine."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "This is a major corporate milestone for ESBATech. After having developed a repeatable technology platform for therapeutic antibody fragments, we started preclinical development of ESBA105 in mid 2006. Now to move this swiftly into the clinic is a truly exciting time for the company. ESBA105 represents a new generation of antibody fragment therapeutics that have favourable biochemical properties over earlier classes of antibody fragments, such as high stability, solubility and high monomeric content. This allows us to deliver the drug topically, without any need to stabilize or modify the protein. Thanks to the small protein size as compared to conventional antibodies, ESBA105 efficiently penetrates into all segments of the eye, which results in a high local concentration where the drug is needed to inhibit inflammation. As this is associated with low systemic drug exposure, this novel therapeutic approach has a very low risk of provoking systemic adverse effects."

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragments frameworks. The company is advancing a pipeline of novel, antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest and VI Partners. For more information about ESBATech, please visit, http://www.esbatech.com.


'/>"/>
SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... CHAPEL HILL, N.C. , Feb. 12, 2016  Clinical Affairs ... their clinical presence in emerging areas of the world. While some ... regions, others lag in their clinical activity in countries such as ... China and India ... approvals to market products in those countries. --> ...
(Date:2/12/2016)... , Feb. 12, 2016   National Community Pharmacists ... RPh, MBA issued the following statement today in response ... by the Centers for Medicare & Medicaid Services ... NCPA, beneficiary advocates and others: patient advocacy ... are still reviewing the full CMS analysis. Our initial ...
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s ... Buddha, the biography of Rama - Dr. Frederick Lenz. , According to ... of a Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... , ... February 12, 2016 ... ... today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced ... will recruit top students from U.S. universities who will draw from Siemens’ ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, ...
Breaking Medicine News(10 mins):